Evidence map›Paper›PMID 35972242›Full record

ArticleAntimicrobial agents and chemotherapy2022

A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant

Steven Park, Riccardo Russo, Landon Westfall, Riju Shrestha, Matthew Zimmerman, Veronique Dartois, Natalia Kurepina, Barry Kreiswirth, Eric Singleton, Shao-Gang Li and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Steven ParkCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Riccardo RussoDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Landon WestfallSouthern Research, Infectious Disease Research, Birmingham, Alabama, USA.
Riju ShresthaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Veronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0001-9470-5009
Natalia KurepinaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Barry KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Eric SingletonDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Shao-Gang LiDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Nisha MittalDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Yong-Mo AhnDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Joseph BilottaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
Kristie L ConnollyDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA.
Ann E JerseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA.
Joel S FreundlichDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-1268-5524
Rutgers, The State University of New Jersey · USHackensack Meridian Health · USUniformed Services University of the Health Sciences · USSouthern Research Institute · US

Funding

Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9M
NIAID NIH HHS U19 AI109713
6 · The paper itself

Abstract

Drug-resistant Neisseria gonorrhoeae is a serious global health concern. New drugs are needed that can overcome existing drug resistance and limit the development of new resistances. Here, we describe the small molecule tricyclic pyrimidoindole JSF-2414 [8-(6-fluoro-8-(methylamino)-2-((2-methylpyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-4-yl)-2-oxa-8-azaspiro[4.5]decan-3-yl)methanol], which was developed to target both ATP-binding regions of DNA gyrase (GyrB) and topoisomerase (ParE). JSF-2414 displays potent activity against N. gonorrhoeae, including drug-resistant strains. A phosphate pro-drug, JSF-2659, was developed to facilitate oral dosing. In two different animal models of Neisseria gonorrhoeae vaginal infection, JSF-2659 was highly efficacious in reducing microbial burdens to the limit of detection. The parent molecule also showed potent

Indexed as

GonorrheaMethicillin-Resistant Staphylococcus aureusProdrugsAdenosine TriphosphateAnimalsAnti-Bacterial AgentsDNA GyraseDrug Resistance, BacterialFemaleMethanolMicrobial Sensitivity TestsNeisseria gonorrhoeaePhosphatesTopoisomerase II InhibitorsAdenosine TriphosphateAnti-Bacterial AgentsDNA GyraseMethanolPhosphatesProdrugsTopoisomerase II InhibitorsC. difficilegyraseNeisseriaNeisseria gonorrhoeaetopoisomeraseVRSA

Identifiers

PMID35972242
PMCPMC9487510
OpenAlexW4291964153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.